T. Klopsch

Therapeutic advances in rheumatoid arthritis

Rheumatoid arthritis: pathogenesis and therapeutic advances

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?